Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
VedaBio
AddedFeb 17, 2024
UpdatedJul 3, 2026
VedaBio

VedaBio

Series A

San Diego-based VedaBio revolutionizes molecular biology with its innovative, accurate, and rapid detection software.

HQ
San Diego, CA, US
Founded
2021
Accelerator
Y Combinator logoY CombinatorS21
Overview
Compare
Fundraising
Employees
Website

Founded in San Diego, California, VedaBio is dedicated to revolutionizing molecular biology through its innovative detection software. The company's core mission is to provide ultra-rapid, accurate molecular detection of highly multiplexed analytes without the need for target amplification. Their flagship product, the CRISPR Cascade™, leverages engineered CRISPR enzymes to deliver near-instant results, aiming to transform the landscape of molecular diagnostics and research.

VedaBio has garnered attention from notable figures and investors in the biotech industry, contributing to its credibility and growth. The company has achieved significant milestones in developing its CRISPR-based detection platform, setting new standards for speed and accuracy in molecular biology. VedaBio's impact is evident in its potential to streamline diagnostic processes and enhance research capabilities, positioning it as a key player in the field of molecular detection.

VedaBio - Similar Companies

Caspr logo

Caspr

Crispr QC logo

Crispr QC

crisprqc.com

Genendeavor logo

Genendeavor

genendeavor.com

Vetica Labs logo

Vetica Labs

Synthego logo

Synthego

synthego.com

Mammoth Biosciences logo

Mammoth Biosciences

Sherlock Biosciences logo

Sherlock Biosciences

OmniVis logo

OmniVis

Vedanta Biosciences logo

Vedanta Biosciences

vedantabio.com

Codetta logo

Codetta

codettabio.com

Acrigen Biosciences logo

Acrigen Biosciences

acrigen.com

Delve Bio logo

Delve Bio

delve.bio

Bioinformatics logo

Bioinformatics

bioinfoinc.com

Entwine Bio logo

Entwine Bio

entwine.bio

Amber Bio logo

Amber Bio

amber.bio

VedaBio - Quick Facts

Who are VedaBio's competitors?

Companies similar to VedaBio include Caspr, Crispr QC, Genendeavor and Vetica Labs.

When was VedaBio founded?

VedaBio was founded in 2021.

Where is VedaBio's headquarters located?

VedaBio's headquarters is located in San Diego, CA, US.

When was VedaBio's last funding round?

VedaBio's most recent funding round was for $40M (USD) in October 2023.

How much has VedaBio raised to-date?

As of Oct 17, 2023, VedaBio has raised a total of $40.1M (USD).

How many employees does VedaBio have?

VedaBio has 5 employees as of Feb 24, 2024.

VedaBio - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Crispr
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Detection Software
  • Diagnostics
  • Medical Tests
Tags
  • Biotech
  • Healthtech
  • Research
  • Software
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 8000Health Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7371Computer Programming Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 623000Nursing and Residential Care Facilities
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software